Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Aimee Johnson (NPI 1427539261)

Field	Value
Entity Type	Individual
Organization	Aimee Johnson
Address	1640 Cowles St Ste 1
City	Fairbanks
State	AK
ZIP	99701
Taxonomy	Physician Assistant
NPI Enumerated	August 28, 2018

Payer Source	Total Paid
Medicare	$914.7K
Medicaid	$0

Key Findings

This provider is effectively a single-payer Medicare practice: lifetime Medicare revenue is $914.7K while there is no Medicaid billing on file. The absence of Medicaid activity means state-level Medicaid competitive comparisons are not possible and the practice appears dependent on Medicare reimbursement for all recorded public-payer revenue.

Revenue is highly concentrated in a small set of drug and office-visit codes: the precomputed top three Medicare codes account for 92.3% of total Medicare revenue. Those top three are J9271 ($670.8K, 73.5% of Medicare revenue), J0897 ($127.4K, 14.0%), and 99214 ($44.2K, 4.8%), indicating most dollars come from a single infused agent and a supporting drug plus E/M visits.

J9271 dominates the revenue profile and billing pattern: the provider reported 15.6K claims for J9271 at $43 avg paid/claim generating $670.8K in revenue, which is 73.5% of this provider's Medicare receipts. Nationally J9271 ranks #640 of 1841 (65th percentile; typical, unremarkable volume for this code), so the provider is a sizable but not dominant national participant for pembrolizumab administration.

The service mix reflects an infusion/oncology-focused workflow supported by chemotherapy administration and infusion codes: 96413 appears with 249 claims and $23.9K revenue (2.6% of Medicare revenue) and 96365 appears with 130 claims and $5.9K revenue (0.6%). These chemotherapy and infusion administration codes, together with high-volume J9271 and J0897, are consistent with an outpatient infusion suite model that bills per-mg drug units plus procedural administration fees.

Competitive standing varies by code: J0897 is relatively higher in percentile reach at rank #1856 of 10057 (81th percentile; typical, unremarkable volume for this code), suggesting stronger national presence for denosumab dosing, while the E/M code 99214 ranks #62427 of 479517 (87th percentile; typical, unremarkable volume for this code), indicating above-average office-visit volume versus national peers. At the same time, several chemotherapy add-on and infusion-hour codes sit in mid-to-lower percentiles (for example 96413 at the 69th percentile and 96415 at the 29th percentile; all labeled typical, unremarkable volume), so the provider is not a top outlier in procedural intensity.

The E/M mix indicates the practice manages returning patients more than high-volume new patient consultations: 99214 accounts for 429 claims and $44.2K revenue while high-complexity new patient code 99205 shows only 11 claims and $2.1K revenue (ranked at the 0th percentile; typical, unremarkable volume for this code). This suggests workflow prioritizes established patient visits and treatment encounters associated with ongoing infusion regimens rather than front-end consult volume.

Operational billing characteristics for infused oncology drugs are apparent in the per-unit payment pattern: many J9271 claims (15.6K) at a relatively low $43 avg paid/claim produced the bulk of revenue ($670.8K), consistent with per-mg billing of high-cost biologics that are itemized in many small units. Analysts should interpret the large claim count alongside drug billing conventions rather than as high per-claim reimbursement.

Tenure and stability: the provider's NPI was enumerated on 2018-08-28 (~8 years ago), indicating multiple years of recorded Medicare activity and an established billing history during the observed period. The combination of sustained drug administration codes and consistent E/M volume supports a steady outpatient infusion practice rather than a transient or newly established operation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

34 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	15,600	$40	$670.8K
J0897	Injection, denosumab, 1 mg	7,080	$20	$127.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	430	$100	$44.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	250	$100	$23.9K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	70	$130	$9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	80	$70	$5.9K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	130	$50	$5.8K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	240	$10	$2.8K
96367	The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose…	120	$20	$2.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	20	$160	$2.3K

Showing 1–10 of 34

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 34 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Aimee Johnson — 1 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

34 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	6	10	13,300	$40	$609.5K
J0897	7	30	2,700	$20	$82.7K
96413	11	20	230	$110	$30.2K
99214	101	1,210	90	$100	$16.2K
J9217	19	20	100	$130	$14.8K
99215	348	400	40	$150	$11K
99213	590	1,290	70	$70	$8.5K
99205	128	140	30	$190	$7.4K
96417	15	20	100	$60	$5.3K
96365	8	30	70	$50	$4.8K

Showing 1–10 of 34

Related Providers

Other providers that share a Tax Identification Number (TIN) with Aimee Johnson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
W William Cox	AK	Hematology & Oncology Physician	$472.4K	$0
Angela Emerson	AK	Physician Assistant	$403.8K	$0
Jacqueline Cox	AK	Hematology & Oncology Physician	$403.3K	$0
Britni Browning	AK	Physician Assistant	$256.7K	$0
Dennis Beckworth	GU	Medical Oncology Physician	$6K	$0

Nearby Providers

Other providers in the same ZIP code as Aimee Johnson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tanana Chiefs Conference	AK	Multi-Specialty Clinic/Center	$0	$107.5M
Fairbanks Memorial Hospital, LLC	AK	General Acute Care Hospital	$0	$83.6M
Fairbanks Resource Agency Inc	AK	Community/Behavioral Health Agency	$0	$48M
Presbyterian Hospitality House	AK	Emotionally Disturbed Childrens' Residential Treatment Facility	$0	$34.9M
Fairbanks Native Association	AK	Substance Abuse Rehabilitation Facility	$0	$32.6M
Tanana Chiefs Confenerce	AK	Transportation Broker	$0	$24.1M
Tanana Chiefs Conference	AK	Community/Behavioral Health Agency	$0	$17M
Tanana Chiefs Conference	AK	Multi-Specialty Clinic/Center	$0	$16.3M
Restore LLC	AK	Substance Use Disorder Rehabilitation Clinic/Center	$0	$16.3M
Tanana Valley Clinic LLC	AK	Multi-Specialty Clinic/Center	$0	$15.2M

Aimee Johnson — Billing Profile & Reimbursement Data

Sign up for Aimee Johnson — Billing Profile & Reimbursement Data policy alerts

Aimee Johnson — Billing Profile & Reimbursement Data

Sign up for Aimee Johnson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References